Equivalence of ELISpot assays demonstrated between major HIV network laboratories

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Gill, Dilbinder K ^a   Huang, Yunda ^b   Levine, Gail L ^c   Sambor, Anna ^c   Carter, Donald K ^d   Sato, Alicia ^b   Kopycinski, Jakub ^a   Hayes, Peter ^a   Hahn, Bridget ^d   Birungi, Josephine ^e   Tarragona Fiol, Tony ^a   Wan, Hong ^a   Randles, Mark ^a   Cooper, Andrew Raxworthy ^a   Ssemaganda, Aloysius ^e   Clark, Lorna ^a   Kaleebu, Pontiano ^e   Self, Steven G ^b   Koup, Richard ^f   Wood, Blake ^b   McElrath, M Juliana ^d   Cox, Josephine H ^a   Hural, John ^d   Gilmour, Jill ^a   more..

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Statistical Center for HIV/AIDS Research and Prevention   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f Vaccine Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; GAMMA INTERFERON;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG RESPONSE; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERMETHOD COMPARISON; LABORATORY TEST; NONHUMAN; PILOT STUDY; QUALITATIVE ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LABORATORY; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; REPRODUCIBILITY; SERODIAGNOSIS; STANDARD; STATISTICAL MODEL; T LYMPHOCYTE;

AIDS SERODIAGNOSIS; AIDS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNE SYSTEM; INTERFERON-GAMMA; LABORATORIES; LEUKOCYTES, MONONUCLEAR; MODELS, STATISTICAL; PILOT PROJECTS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES;

EID: 78650779470     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014330     Document Type: Article

References (25)

1. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, et al. (2003) Medicine. The need for a global HIV vaccine enterprise. Science 300: 2036-2039.
2. Esparza J (2005) The global HIV vaccine enterprise. Int Microbiol 8: 93-101.
3. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, et al. (2003) The Need for a Global HIV Vaccine Enterprise. Science 300: 2036-2039.
4. Stiles T, Grant V, Mawbey N (2003) Good Clinical Laboratory Practice (GCLP). A Quality System for Laboratories which undertake the Analyses of Samples from Clinical Trials. BARQA. pp 1-17.
5. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, McElrath MJ (2003) Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis 187: 226-242.
6. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65: 109-121.
7. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, et al. (2006) Combination immunotherapy with prostatic acid phosphatase pulsed antigenpresenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107: 67-74.
8. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80: 4717-4728.
9. Streeck H, Frahm N, Walker BD (2009) The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 4: 461-469.
10. Todryk SM, Walther M, Bejon P, Hutchings C, Thompson FM, et al. (2009) Multiple functions of human T cells generated by experimental malaria challenge. Eur J Immunol 39: 3042-3051.
11. Smith JG, Levin M, Vessey R, Chan IS, Hayward AR, et al. (2003) Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization. J Med Virol 70 Suppl 1: S38-41.
12. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, et al. (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21: 68-81.
13. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, et al. (2008) Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57: 303-315.
14. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
15. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, et al. (2009) Concordant Proficiency in Measurement of T-Cell Immunity in Human Immunodeficiency Virus Vaccine Clinical Trials by Peripheral Blood Mononuclear Cell and Enzyme-Linked Immunospot Assays in Laboratories from Three Continents. Clin Vaccine Immunol 16: 147-155.
16. Dubey S, Clair J, Fu TM, Guan L, Long R, et al. (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr May 1;45(1): 20-7.
17. Bull M, Lee D, Stucky J, Chiu YL, Rubin A, et al. (2007) Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J Immunol Methods 322: 57-69.
18. Currier J, Kuta E, Turk E, Earhart L, Loomis-Price L, et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172.
19. Moodie Z, Huang Y, Gu L, Hural J, Self SG (2006) Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods 315: 121-132.
20. Agresti A, Min Y (2005) Simple improved confidence intervals for comparing matched proportions. Stat Med 24: 729-740.
21. Lin LI (1989) A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 255-268.
22. Herr W, Linn B, Leister N, Wandel E, et al. (1997) The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumour necrosis factor a spots in response to peptide antigens. J Immunol Methods 203: 141-152.
23. Almeida CA, Roberts SG, Laird R, McKinnon E, Ahmed I, et al. (2009) Automation of the ELISpot assay for high-throughput detection of antigenspecific T-cell responses. J Immunol Methods 344: 1-5.
24. Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, et al. (2007) Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res Hum Retroviruses 23: 86-92.
25. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, et al. (2009) ''MIATA''-minimal information about T cell assays. Immunity 31: 527-528.